Share This Page
Drugs in ATC Class N01AF
✉ Email this page to a colleague
Drugs in ATC Class: N01AF - Barbiturates, plain
| Tradename | Generic Name |
|---|---|
| BREVITAL SODIUM | methohexital sodium |
| METHOHEXITAL SODIUM | methohexital sodium |
| PENTOTHAL | thiopental sodium |
| >Tradename | >Generic Name |
ATC Class N01AF (Barbiturates) Plain: Market Dynamics and Patent Landscape (Generics, Formulations, and Method Patents)
Executive summary
ATC class N01AF (barbiturates), plain is dominated by older, off-patent small-molecule sedatives and anesthetics whose core API compositions generally lack active primary composition-of-matter exclusivity in major markets. The competitive battleground is largely regulatory exclusivity, product-specific formulation/process patents, labeling and controlled-substance distribution constraints, and sporadic Paragraph IV and reformulation litigation. Patent value is concentrated in specific dosage forms (injectables, tablets, compounded kits) and manufacturing/process improvements, not the base barbiturate structures.
Which barbiturates are included in ATC N01AF and how is the market structured?
ATC N01AF groups barbiturates, plain (single active ingredient) used across anesthesia adjuncts, procedural sedation in limited settings, and off-label/legacy indications, with use and availability shaped by controlled-substance schedules and historical prescribing patterns.
Market structure (high level)
- API and product: Most products are generic or authorized generics using mature manufacturing routes.
- Primary demand drivers: Hospital formularies, procedural sedation protocols, anesthesiology back-up stocks, and regional availability.
- Supply constraints: Sterile manufacturing capability, stability requirements, and controlled distribution.
- Pricing: Low unit pricing, higher dependence on contracting and inventory decisions than innovation differentiation.
Common practical product categories within N01AF
Barbiturate “plain” products typically break into:
- Injectables (critical for OR and emergency workflows; higher barrier to entry due to sterile-process validation and stability)
- Oral tablets/capsules (lower manufacturing barrier; more direct generic competition)
What patents protect barbiturates (N01AF) “plain” products and where does IP still matter?
Core point: For most barbiturates in N01AF, composition-of-matter protection from early filings has largely expired. Where patents remain relevant, they are usually product- or process-specific.
Patent clusters that still show up for N01AF
- Formulation patents
- Solubilization of poorly soluble barbiturates (especially injectables)
- Stabilizers and pH buffers
- Particle-size or crystal form control for solids (more common in other small molecules; less consistent for legacy barbiturates but still appears)
- Manufacturing process patents
- Sterile filtration steps, lyophilization cycles, or aseptic fill process windows
- Impurity control methods that reduce degradation products
- Packaging and delivery
- Container-closure systems to reduce adsorption or leachables
- Compatibility solutions for co-administered fluids
- Method-of-use or administration protocols
- Dosing regimens or monitoring steps are less common for old agents but can exist as secondary patents tied to specific product labeling strategies
IP value chain implication
For new entrants or licensors, the “real” IP diligence target is rarely the barbiturate scaffold and more often:
- the particular NDC strength and dosage form
- the sterile formulation and manufacturing method
- and the FDA labeling and REMS-like operational controls (rare for classic barbiturates, but distribution/controlled-substance constraints often function as de facto entry barriers).
When does exclusivity or last patent protection end for barbiturates in N01AF?
Core point: In this class, exclusivity is generally driven by:
- old NDA/ANDA exclusivities that are largely expired
- plus any later-granted formulation/process patents that can extend practical exclusivity for specific products for limited periods (often into late 2020s or beyond depending on filing dates of incremental patents).
How to think about “exclusivity” in N01AF
- Regulatory exclusivity (NDA/505(b)(1) or 505(b)(2)): Most legacy barbiturate approvals predate modern exclusivity frameworks.
- Patent exclusivity (Orange Book patents tied to specific listed products): More product-specific and more likely to create short-to-medium-term barriers.
- Practical exclusivity from supply: Even absent patents, supply and quality systems can limit entry.
What is the Orange Book status of ATC N01AF barbiturates (and how many listed patents usually exist per product)?
For ATC N01AF, Orange Book listings typically show:
- multiple listed patents per dosage form and strength even when composition-of-matter is expired
- with listings skewed toward formulation, process, and method-of-use.
Typical pattern
- Older base APIs: few or no active composition patents
- Injectables: more likely to have formulation/process patents still listed
- Solid oral forms: fewer late-stage patents, more reliance on generic competition
Because Orange Book status is NDC-specific and jurisdiction-specific, the operational approach for market entry is to map:
- the targeted NDC strength
- to the listed active patent set
- to the expected generic 505(b)(2) or ANDA route.
How do generic entry risks work for N01AF barbiturates (Paragraph IV, litigation, settlements)?
Paragraph IV likelihood
For N01AF, Paragraph IV is less frequent in modern cycles because:
- many products are already generic
- existing active patents, when any, are often narrow and easier to design around
When Paragraph IV occurs, it typically targets:
- a listed formulation/process patent
- or a method-of-use/administration-related claim tied to labeling.
Litigation and settlement dynamics
Where patent disputes occur, outcomes commonly include:
- noninfringement/invalidity settlements
- launch carve-outs by strength or dosage form
- design-around of excipients or manufacturing steps
Market impact
- Settlements affect timing of entry by months to 1-2 years more often than long-term multi-year delays, reflecting narrow patent scope and the already-mature generic landscape.
What formulations are likely protected (injectables vs oral) for N01AF barbiturates?
Injectable barbiturates: typical protection targets
- Solubility and stability systems (buffers, cosolvents)
- Antioxidant or degradation-control strategies
- Sterility assurance and impurity profile controls
- Container-closure compatibility
Oral barbiturates: typical protection targets
- Bioavailability or dissolution enhancements (where formulation differences exist)
- Manufacturing impurity and particle control (less consistently patent-rich than injectables for legacy agents)
- Labeling-driven method patents (if any)
Which companies dominate N01AF barbiturate supply, and how does patent status affect competitive positioning?
Market share tends to be driven by:
- contract awards
- hospital procurement relationships
- sterile manufacturing capacity (injectables)
- distribution reliability for controlled substances
In practice, patent status mostly impacts:
- whether a competitor can launch a specific strength/dosage form NDC quickly
- whether it must file 505(b)(2) with bridging or reformulation rather than a clean ANDA.
How does ATC N01AF compare with other barbiturate-adjacent ATC classes on IP and competition?
Relative IP intensity
- N01AF (“barbiturates plain”) is generally more commoditized than combinations or newer derivatives because its assets are legacy.
- Adjacent classes that include barbiturate combinations or newer CNS sedatives often show higher rates of:
- combination-specific formulation IP
- more recent method-of-use or controlled-release systems.
Practical business implication
Competition intensity in N01AF is usually:
- high on pricing for oral solids
- mixed on injectables where quality and supply constraints can outperform price competition.
What FDA regulatory pathways shape market dynamics for N01AF generics?
Entry pathways
- ANDA (505(j)): most common for generic substitution of established barbiturate drugs with mature DMFs and manufacturing routes.
- 505(b)(2): used when bridging to a reference listed drug requires reformulation justification or when certain formulation attributes differ.
Labeling and reference product controls
Even when patents are expired, FDA review can slow entry if:
- stability data do not match
- impurity profiles differ
- sterility assurance requires reformulated process verification.
What patent expiration dates matter most for a barbiturate new entrant?
Core point: The only dates that matter operationally are those tied to:
- the exact NDC(s) you want
- the active Orange Book patents listed for those NDCs
- and any triggered litigation stay conditions tied to paragraph IV notice or settlement timing.
In N01AF, expiration dates usually fall into two buckets:
- early composition patents already expired
- later formulation/process patents with residual term for injectable or specific strengths
Key Takeaways
- N01AF barbiturates, plain are largely off-patent at the API composition level; patent value is concentrated in formulation/process and sometimes method-of-use for specific dosage forms.
- Generic competition is structurally strong; entry timing is driven mainly by Orange Book listings per NDC, the ability to design around formulation/process claims, and FDA stability/CMC readiness.
- For business planning, focus diligence on injectable versus oral product lines and on NDC-specific patent sets, not on the barbiturate scaffold.
FAQs
-
What type of patents are most common for generic barbiturate injectables?
Formulation and manufacturing/process patents tied to solubilization, stability, impurity control, and sterile/aseptic fill processes. -
Do Paragraph IV challenges occur for ATC N01AF products today?
They occur when there are active, NDC-specific listed patents, but overall incidence is lower because many products are already generic. -
Can a generic launch avoid barbiturate formulation patents by changing excipients?
Sometimes, but success depends on claim scope, manufacturing comparability, and FDA CMC requirements for stability and impurity profiles. -
Are controlled-substance constraints an IP substitute for N01AF market exclusivity?
They can function as practical barriers by limiting distribution and requiring reliable controlled handling, even when patents are expired. -
Which N01AF dosage forms face the highest regulatory and IP entry barriers?
Sterile injectables, due to CMC complexity and any formulation/process patent coverage that is often product-specific.
References (APA)
- FDA. (n.d.). Drugs@FDA (Orange Book-linked product and approval information). U.S. Food and Drug Administration.
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- U.S. Food and Drug Administration. (n.d.). ANDA and 505(j) guidance and regulatory pathway materials. FDA.
- U.S. Patent and Trademark Office. (n.d.). Patent examination and assignment records. USPTO.
More… ↓
